Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

Blood

Volumn 98, Issue 6, 2001, Pages 1746-1751

  San Miguel, Jesús F ^{a,b,c,d,e,f,g}   Vidriales, María B ^a,b,c,d,e,f   López Berges, Consuelo ^a,b,c,d,e,f   Díaz Mediavilla, Joaquín ^a,b,c,d,e,f   Gutiérrez, Norma ^a,b,c,d,e,f   Cañizo, Consuelo ^a,b,c,d,e,f   Ramos, Fernando ^{a,b,c,d,e,f,g}   Pérez, José J ^a,b,c,d,e,f   González, Marcos ^a,b,c,d,e,f   Orfao, Alberto ^a,b,c,d,e,f  

^a University Hospital   (Mexico)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e Servicio de Urología   (Mexico)

^f HOSPITAL GENERAL DE SEGOVIA   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; IDARUBICIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; DISEASE CLASSIFICATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 0035885973     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1746     Document Type: Article

References (30)

1. Cavé H, Van der Werff J, Bosch T, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med.1998;339:591-598.
2. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550-554.
3. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997;90:2465-2470.
4. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12-22.
5. Ciudad J, San Miguel JF, López-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol. 1998;16:3774-3781.
6. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual in acute lymphoblastic leukemia in childhood: a prospective study of the International BFM study group. Lancet. 1998;352:1731-1738.
7. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all-trans retinoic (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
8. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-1253.
9. Sievers EL, Lange BJ, Buckley JD, et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst. 1996;88:1483-1488.
10. Reading CL, Estoy EH, Huh YO, et al. Expression of unusual immunophenotype combinations of acute myelogenous leukemia. Blood. 1993;81:3083-3090.
11. San Miguel JF, Gonzalez M, Orfao A. Minimal residual disease in myeloid malignancies. In: Linch LH, Löwenberg B, eds. Textbook of Malignant Haematology. London, UK: Martin Dunitz; 1999:871-891.
12. San Miguel JF, Ciudad J, Vidriales MB, et al. Immunophenotypical detection of minimal residual disease in acute leukemia. Crit Rev Oncol Hematol. 1999;32:175-185.
13. Macedo A, Orfao A, Vidriales MB, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol. 1995;70:189-194.
14. Macedo A, San Miguel JF, Vidriales MB, et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol. 1996;49:15-18.
15. Orfao A, Schmitz G, Brando B, et al. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem. 1999;45:1708-1717.
16. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after one week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995;86:1292-1295.
17. Panzer-Grümayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.
18. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol. 1999;10:69-79.
19. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood. 2000;95:72-77.
20. Harris LN, Jaffe E, Dielbold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic diseases and lymphoid tissues: report of the clinical advisory committee meeting. J Clin Oncol. 1999;17:3835-3849.
21. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
22. Cheson BD, Cassilth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
23. Macedo A, Orfao A, Gonzalez M, et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia. 1995;9:993-998.
24. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
26. Van Dongen JJM, Macintyre EA, Delabesse E, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease: report of the BIOMED-1 Concerted Action investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
27. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17-31.
28. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
29. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
30. Lucio P, Parreira A, van den Beemd MW, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor B-ALL. Leukemia. 1999;13:419-427.